Injections of the selective adenosine A2A antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor suppression induced by haloperidol in rats

Behavioural Brain Research

Volumn 178, Issue 2, 2007, Pages 190-199

  Ishiwari, Keita ^a   Madson, Lisa J ^a   Farrar, Andrew M ^a   Mingote, Susana M ^a   Valenta, John P ^a   DiGianvittorio, Michael D ^a   Frank, Lauren E ^a   Correa, Merce ^a,c   Hockemeyer, Jörg ^b   Müller, Christa ^b   Salamone, John D ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITAT JAUME I   (Spain)

Author keywords

Antipsychotic; Basal ganglia; Caudate putamen; D2 receptor; Dopamine; Neostriatum; Parkinson's disease

Indexed keywords

ADENOSINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; MSX 3; PHOSPHORIC ACID [3 [8 [2 (3 METHOXYPHENYL)VINYL] 7 METHYL 2,6 DIOXO 1 PROP 2 YNYL 1,2,6,7 TETRAHYDROPURIN 3 YL]PROPYL] ESTER DISODIUM SALT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG SELECTIVITY; LOCOMOTION; MALE; NEUROMODULATION; NONHUMAN; NUCLEUS ACCUMBENS; PARKINSONISM; PRIORITY JOURNAL; RAT;

ANALYSIS OF VARIANCE; ANIMALS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HALOPERIDOL; INJECTIONS, INTRAPERITONEAL; MALE; MICROINJECTIONS; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR CROSS-TALK; RECEPTOR, ADENOSINE A2A; XANTHINES;

EID: 33847398616     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2006.12.020     Document Type: Article

References (82)

1. Annett L.E., Ridley R.M., Gamble S.J., and Baker H.F. Social withdrawal following amphetamine administration to marmosets. Psychopharmacology 99 (1989) 222-229
2. Antoniou K., Papadopoulou-Daifoti Z., Hyphantis T., Papathanasiou G., Bekris E., Marselos M., et al. A detailed behavioral analysis of the acute motor effects of caffeine in the rat: involvement of adenosine A1 and A2A receptors. Psychopharmacology 183 (2005) 154-162
3. Aoyama S., Kase H., and Borrelli E. Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J Neurosci 20 (2000) 5848-5852
4. Bakshi V.P., and Kelley A.E. Dopaminergic regulation of feeding behavior: I. Differential effects of haloperidol microinjection in three striatal subregions. Psychobiology 19 (1991) 223-232
5. Baldo B.A., Sadeghian K., Basso A.M., and Kelley A.E. Effects of selective dopamine D1 or D2 receptor blockade within nucleus accumbens subregions on ingestive behavior and associated motor activity. Behav Brain Res 137 (2002) 165-177
6. Barraco R.A., Martens K.A., Parizon M., and Normile H.J. Adenosine A2a receptors in the nucleus accumbens mediate locomotor depression. Brain Res Bull 31 (1993) 397-404
7. Barraco R.A., Martens K.A., Parizon M., and Normile H.J. Role of adenosine A2a receptors in the nucleus accumbens. Prog Neuropsychopharmacol Biol Psychiat 18 (1994) 545-553
8. Bezchlibnyk-Butler K.Z., and Remington G.J. Antiparkinsonian drugs in the treatment of neuroleptic-induced extrapyramidal symptoms. Can J Psychiat 39 (1994) 74-84
9. Bokobza B., Ruberg M., Scatton B., Javoy-Agid F., and Agid Y. [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. Eur J Pharmacol 99 (1984) 167-175
10. Brunt E.R., Brooks D.J., Korczyn A.D., Montastruc J.L., and Stocchi F. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. J Neural Transm 109 (2002) 489-502
11. Carlson B.B., Wisniecki A., and Salamone J.D. Local injections of the 5-hydroxytryptamine antagonist mianserin into substantia nigra pars reticulata block tremulous jaw movements in rats: studies with a putative model of Parkinsonian tremor. Psychopharmacology 165 (2003) 229-237
12. Carlson B.B., Behrstock S., Tobin A.J., and Salamone J.D. Brain implantations of engineered GABA-releasing cells suppress tremor in an animal model of Parkinsonism. Neuroscience 119 (2003) 927-932
13. Carta A.R., Pinna A., Cauli O., and Morelli M. Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-DOPA and A(2A) receptor blockade plus L-DOPA in dopamine-denervated rats. Synapse 44 (2002) 166-174
14. Cenci M.A., Whishaw I.Q., and Schallert T. Animal models of neurological deficits: how relevant is the rat?. Nat Rev Neurosci 3 (2002) 574-579
15. Chen J.F., Moratalla R., Impagnatiello F., Grandy D.K., Cuellar B., Rubinstein M., et al. The role of the D2 dopamine receptor (D2R) in A2a adenenosine-receptor (A2aR) mediated behavioral and cellular responses as revealed by A2a and D2 receptor knockout mice. Proc Natl Acad Sci 98 (2001) 1970-1975
16. Correa M., Carlson B.B., Wisniecki A., and Salamone J.D. Nucleus accumbens dopamine and work requirements on interval schedules. Behav Brain Res 137 (2002) 179-187
17. Correa M., Arizzi M.N., Betz A., Mingote S., and Salamone J.D. Locomotor stimulant effects of intraventricular injections of ethanol in rats: acute and repeated administration. Psychopharmacology 170 (2003) 368-375
18. 2A antagonist KF 17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism. Behav Brain Res 148 (2004) 47-54
19. Cousins M.S., Sokolowski J.D., and Salamone J.D. Different effects of nucleus accumbens and ventrolateral striatal dopamine depletions on instrumental response selection in the rat. Pharmacol Biochem Behav 46 (1993) 943-951
20. Cousins M.S., and Salamone J.D. Involvement of ventrolateral striatal dopamine in movement initiation and execution: a microdialysis and behavioral investigation. Neuroscience 70 (1996) 849-859
21. Cousins M.S., Finn M., Trevitt J., Carriero D.L., Conlan A., and Salamone J.D. The role of ventrolateral striatal acetylcholine in the production of tacrine-induced jaw movements. Pharmacol Biochem Behav 62 (1999) 439-447
22. DeLong M.R. Primate model of movement disorders of basal ganglia origin. Trends Neurosci 13 (1990) 281-285
23. 2A receptor antagonism reverses the effects of dopamine receptor antagonism on instrumental output and effort-related choice in the rat. Implications for studies of psychomotor slowing. Psychopharmacology, 2007, in press.
24. Ferré S., Freidholm B.B., Morelli M., Popoli P., and Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 20 (1997) 482-487
25. Ferré S., Popoli P., Gimenez-Llort L., Rimondini R., Müller C.E., Stromberg I., et al. Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease. Parkinson Rel Disord 7 (2001) 235-241
26. Finn M., Jassen A., Baskin P., and Salamone J.D. Tremulous characteristic of vacuous jaw movements induced by pilocarpine and ventrolateral striatal dopamine depletions. Pharmacol Biochem Behav 57 (1997) 243-249
27. Fink J.S., Weaver D.R., Rivkees S.A., Peterfreund R.A., Pollack A.E., Adler E.M., et al. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res 14 (1992) 186-195
28. 2A/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia. Brain Res Rev 26 (1998) 258-273
29. 2A receptor antagonist in MPTP-treated monkeys. Neurology 52 (1999) 1673-1677
30. 2A receptors in the caudate-putamen. Neuroreport 9 (1998) 1803-1806
31. 2A receptors in the nucleus accumbens and the caudate-putamen. Eur J Pharmacol 323 (1997) 127-131
32. 2A receptors in the caudate putamen of rats. Eur J Neurosci 14 (2001) 1287-1293
33. 2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J Comp Neurol 431 (2001) 331-346
34. 2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease. J Org Chem 69 (2004) 3308-3318
35. Hornykiewicz O. Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA). Br Med Bull 29 (1973) 172-178
36. Ikemoto S. Ventral striatal anatomy of locomotor activity induced by cocaine, d-amphetamine, dopamine and D1/D2 agonists. Neuroscience 113 (2002) 939-955
37. Ishiwari K., Betz A., Weber S., Felsted J., and Salamone J.D. Pimozide (Orap) shows a pattern of behavioral effects similar to the typical antipsychotic haloperidol: studies with tremulous jaw movements and lever pressing in rats. Pharmacol Biochem Behav (2005)
38. 2A receptor antagonist, for the treatment of Parkinson's disease. Exp Opin Investig Drugs 14 (2005) 729-738
39. Jicha G., and Salamone J.D. Vacuous jaw movements and feeding deficits in rats with ventrolateral striatal dopamine depletions: possible model of parkinsonian symptoms. J Neurosci 11 (1991) 3822-3829
40. 2A receptor antagonist with anticataleptic activity. Eur J Pharm 256 (1994) 262-268
41. 2A receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharm 28 (2003) 1281-1291
42. Kelley A.E., Gauthier A.M., and Lang C.G. Amphetamine microinjections into distinct striatal subregions cause dissociable effects on motor and ingestive behavior. Behav Brain Res 35 (1989) 27-39
43. Kelley A.E., Bakshi V.P., Delfs J.M., and Lang C.G. Cholinergic stimulation of the ventrolateral striatum elicits mouth movements in rats: pharmacological and regional specificity. Psychopharmacology 99 (1989) 542-549
44. Keppel G. Design and analysis: a researchers handbook (1991), Prentice-Hall, Englewood Cliffs, NJ
45. 2A receptor agonist in mice. Neuropharmacology 39 (2000) 1004-1015
46. Koob G.F., Riley S.J., Smith S.C., and Robbins T.W. Effects of 6-hydroxydopamine lesions of the nucleus accumbens septi and olfactory tubercle on feeding, locomotor activity, and amphetamine anorexia in the rat. J Comp Physiol Psychol 92 (1978) 917-927
47. Lang A.E., and Lees A. DA agonists-non-ergot derivatives: Ropinirole. Mov Disord 17 (2002) s98-s102
48. Lang A.E., and Lees A. DA agonists-ergot derivatives: Pergolide. Mov Disord 17 (2002) s79-s82
49. Lillrank S.M., Lipska B.K., Weinberger D.R., Fredholm B.B., Fuxe K., and Ferre S. Adenosine and dopamine receptor antagonist binding in the rat ventral and dorsal striatum: lack of changes after a neonatal bilateral lesion of the ventral hippocampus. Neurochem Int 34 (1999) 235-244
50. Madras B.K., Gracz L.M., Fahey M.A., Elmaleh D., Meltzer P.C., Liang A.Y., et al. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain. Synapse 29 (1998) 116-127
51. Maldonado-Irizarry C.S., and Kelley A.E. Differential behavioral effects following microinjection of an NMDA antagonist into nucleus accumbens subregions. Psychopharmacology 116 (1994) 65-72
52. 2A antagonists in the treatment of movement disorders. CNS Drugs 10 (1998) 311-320
53. Marsden C., Duvoisin R., Jenner P., Parkes J., Pycock C., and Tarsy D. Relationship between animal models and clinical parkinsonism. Adv Neurol 9 (1975) 165-175
54. 1 mechanisms involved in the antiparkinsonian effects of SKF 82958 (APB): studies of tremulous jaw movements in rats. Psychopharmacology 143 (1999) 72-81
55. McGeorge A.J., and Faull R.L.M. Organization of the projection from the cerebral cortex to the striatum in the rat. Neuroscience 29 (1989) 503-537
56. 2A receptors as a basis for the treatment of Parkinson's disease. Neurol Sci 22 (2001) 71-72
57. 2A-selective adenosne receptor antagonists. Drug Dev Res 45 (1998) 190-197
58. Murray T.K., Messenger M.J., Ward M.A., Woodhouse S., Osborne D.J., Duty S., et al. Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease. Pharmacol Biochem Behav 73 (2002) 455-466
59. 2A receptor blockade in the nucleus accumbens on locomotion, feeding, and prepulse inhibition in rats. Synapse 49 (2003) 279-286
60. 2A receptors: implications for the treatment of Parkinson's disease. J Neurosci 20 (2000) 7782-7789
61. 2A receptor antagonists. Life Sci 77 (2005) 3259-3267
62. Pisa M. Motor somatotopy in the striatum of rat: manipulation, biting and gait. Behav Brain Res 27 (1988) 21-35
63. 2A receptors in the rat central nervous system. J Comp Neurol 401 (1998) 163-186
64. Salamone J.D., Johnson C.J., McCullough L.D., and Steinpreis R.E. Lateral striatal cholinergic mechanisms involved in oral motor activities in the rat. Psychopharmacology 102 (1990) 529-534
65. Salamone J.D., Mahan K., and Rogers S. Ventrolateral striatal dopamine depletions impair feeding and food handling in rats. Pharmacol Biochem Behav 44 (1993) 605-610
66. Salamone J.D., Kurth P.A., McCullough L.D., Sokolowski J.D., and Cousins J.D. The role of brain dopamine in response initiation: effects of haloperidol and regionally specific dopamine depletions on local rate of instrumental responding. Brain Res 628 (1993) 218-226
67. Salamone J.D., Mayorga A.J., Trevitt J.T., Cousins M.S., Conlan A., and Nawab A. Tremulous jaw movements in rats; a model of parkinsonian tremor. Prog Neurobiol 56 (1998) 591-611
68. Salamone J., Correa M., Carlson B., Wisniecki A., Mayorga A., Nisenbaum E., et al. Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents. Implications for cholinergic involvement in parkinsonism. Life Sci 68 (2001) 2579-2584
69. Salamone J.D., Carlson B.B., Rios C., Lentini E., Correa M., Wisniecki A., et al. Dopamine agonists suppress cholinomimetic-induced tremulous jaw movements in an animal model of Parkinsonism: tremorolytic effects of pergolide, ropinirole and CY 208-243. Behav Brain Res 156 (2005) 173-179
70. Salamone J.D., Correa M., Mingote S.M., Weber S.M., and Farrar A.M. Nucleus accumbens dopamine and the forebrain circuitry involved in behavioral activation and effort-related decision making: implications for understanding anergia and psychomotor slowing in depression. Curr Psychiatry Rev 2 (2006)
71. Sauer R., Maurinsh J., Reith U., Fulle F., Klotz K.N., and Müller C.E. Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists. J Med Chem 43 (2000) 440-448
72. 2A receptor agonist CGS 21680. Eur J Pharmacol 484 (2004) 269-275
73. 2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology 147 (1999) 90-95
74. 2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions. Exp Neurol 189 (2004) 182-188
75. 2A receptors in dopamine D2 receptor regulation in dopamine-denervated striatum. Eur J Neurosci 12 (2000) 4033-4037
76. 2A receptors. Prog Neurobiol 59 (1999) 355-396
77. Trevitt J.T., Carlson B.B., Correa M., Keene A., Morales M., and Salamone J.D. Interactions between D1 receptors and GABA mechanisms in substantia nigra pars reticulata of the rat: neurochemical and behavioral studies. Psychopharmacology 159 (2002) 229-237
78. Wang W.F., Ishiwata K., Nonaka H., Ishii S., Kiyosawa M., Shimada J., et al. Carbon-11-labeled KF21213: a highly selective ligand for mapping CNS adenosine A(2A) receptors with positron emission tomography. Nucl Med Biol 27 (2000) 541-546
79. Wardas J., Konieczny J., and Lorenc-Koci E. SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats. Synapse 41 (2001) 160-171
80. Wichmann T., Kliem M.A., and DeLong M.R. Antiparkinsonian and behavioral effects of inactivation of the substantia nigra pars reticulata in hemiparkinsonian primates. Exp Neurol 167 (2001) 410-424
81. A antagonism in globus palidus: studies of locomotion and tremulous jaw movements. Psychopharmacology 170 (2003) 140-149
82. Young A.B., and Penney J.B. Biochemical and functional organization of the basal ganglia. In: Jankowic J., and Tolosa E. (Eds). Parkinson's disease and movement disorders (1993), Williams and Wilkins, Baltimore 1-12